Weitz & Luxenberg is gathering information about the train accident in Hoboken, New Jersey. We encourage those involved in the accident to contact the firm about their experiences and how they might have been affected.Read More
Ellen Relkin to Speak at ABA Event in OctoberSeptember 22nd, 2015
W&L Of Counsel attorney Ellen Relkin will be a featured speaker at an October seminar sponsored by the American Bar Association on pharmaceutical, medical device and biotech litigation.
The seminar will address a number of topics of importance to attorneys who focus on cases involving defective drugs and medical devices.
Ms. Relkin is a nationally recognized authority on the prosecution of claims brought against the makers of drugs and devices that were marketed as safe and effective but then turned out to be harmful.
The seminar is set to take place Friday, Oct. 2, at the headquarters of Pfizer, Inc. at 235 E. 42nd Street in New York City. The ABA’s Section of Litigation, Products Liability, is organizing the seminar.
ABA Seminar Will Cover a Range of Topics
According to the ABA, the seminar will cover a range of topics. Among them: risk communication, product recalls and biosimilars. The topics on the panel Ms. Relkin will be speaking on include off-label promotion consisting of truthful speech and the recent Amarin v. FDA ruling and its impact on generic drug litigation; the jury perception of social media as a direct-to-consumer marketing tactic and challenges in monitoring and regulating genetic testing and a company’s duty to recommend genetic testing to patients who can have untoward risks if they have a genetic predisposition that can be identified before taking the medication.
Serves in Leadership Roles
Ms. Relkin’s insights into these and other areas derive from her long years of representing plaintiffs harmed by defective drugs and medical devices.
Her resume includes many leadership roles. For example, Ms. Relkin is the court-appointed co-lead counsel of the In Re: DePuy ASR Multi-District Litigation (MDL). She is also the lead and liaison counsel for the New Jersey In Re: Stryker Rejuvenate & ABG II Modular Hip Implant Litigation. As well, Ms. Relkin is a member of the Plaintiff Steering Committee of the In Re: Xarelto Product Liability Litigation.
Ms. Relkin is certified by the New Jersey Supreme Court as a Civil Trial Attorney. She is active in a number of organizations. For the American Bar Association, she served as co-chair of the Pharmaceutical and Medical Device Subcommittee of the ABA Section of Litigation Mass Torts Committee.
Ms. Relkin lectures nationally at continuing legal education programs. She also lectures annually at the Institute for the New Jersey Institute for Continuing Legal Education’s program on Mass Torts in New Jersey, as well as the law update for the annual New Jersey Trial Lawyers Association Boardwalk convention.